Exact Sciences Corporatio... (EXAS)
NASDAQ: EXAS
· Real-Time Price · USD
56.72
0.53 (0.94%)
At close: Oct 03, 2025, 3:59 PM
56.15
-1.00%
After-hours: Oct 03, 2025, 07:44 PM EDT
Exact Sciences Revenue Breakdown
| Period Ending | Jun 30, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|
| Precision Oncology Revenue | 182.6M | 160.86M | 163.75M | 167.66M | 162.73M | 472.79M | 156.32M |
| Precision Oncology Revenue Growth | +13.52% | -1.77% | -2.33% | +3.03% | -65.58% | +202.44% | n/a |
| Screening Revenue | 628.48M | 552.56M | 544.9M | 531.61M | 474.8M | 1.39B | 472.01M |
| Screening Revenue Growth | +13.74% | +1.41% | +2.50% | +11.96% | -65.91% | +195.05% | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 55.26M | 51.59M | 48.4M | 49.43M | 46.72M | 44.53M | 41.82M | 38.6M | 35.59M | 37.27M | 31.53M | 28.34M | 29.44M | 27.23M | 26.85M | 26.06M | 21.26M | 16.24M | 19.02M | 20.94M |
| Non-Us Revenue Growth | +7.11% | +6.58% | -2.08% | +5.80% | +4.92% | +6.48% | +8.36% | +8.47% | -4.51% | +18.19% | +11.26% | -3.74% | +8.13% | +1.42% | +3.04% | +22.58% | +30.87% | -14.59% | -9.16% | n/a |
| United States Revenue | 755.83M | 655.2M | 665.02M | 659.22M | 652.54M | 592.99M | 605.06M | 589.74M | 586.51M | 565.18M | 491.54M | 493.3M | 457.13M | 429.15M | 407.97M | 376.02M | 445.08M | 392.12M | 249.85M | 326.88M |
| United States Revenue Growth | +15.36% | -1.48% | +0.88% | +1.02% | +10.04% | -1.99% | +2.60% | +0.55% | +3.77% | +14.98% | -0.36% | +7.91% | +6.52% | +5.19% | +8.50% | -15.52% | +13.51% | +56.94% | -23.57% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 450.79M | 485M | 442.51M | 411.9M | 387.13M | 435.5M | 411.03M | 390.55M | 414.45M | 404.26M | 404.11M | 379.7M | 397.6M | 401.98M | 463.67M | 383.12M | 362.43M | 453.84M | 312.28M | 252.08M | 225.55M | 281.75M | 264.26M | 166.8M | 151.92M | 154.97M | 133.21M | 111.54M | 94.03M | 88.97M | 74.37M | 68.57M | 61.33M | 58.9M | 52M | 46.61M | 47.6M | 43.51M | 37.81M | 38.51M | 34.28M | 28.72M |
| Selling, General, and Administrative Revenue Growth | -7.05% | +9.60% | +7.43% | +6.40% | -11.11% | +5.95% | +5.24% | -5.77% | +2.52% | +0.04% | +6.43% | -4.50% | -1.09% | -13.30% | +21.03% | +5.71% | -20.14% | +45.33% | +23.88% | +11.76% | -19.95% | +6.62% | +58.44% | +9.79% | -1.96% | +16.34% | +19.43% | +18.62% | +5.68% | +19.64% | +8.46% | +11.81% | +4.12% | +13.26% | +11.58% | -2.09% | +9.40% | +15.08% | -1.83% | +12.36% | +19.33% | n/a |
| Research and Development Revenue | 108.9M | 105.31M | 99.62M | 100.1M | 120.88M | 110.61M | 114.92M | 111.45M | 104.09M | 95.42M | 94.27M | 90.81M | 106.08M | 102.25M | 88.49M | 75.36M | 106.23M | 115.57M | 446.4M | 31.47M | 32.67M | 43.51M | 43.22M | 34.95M | 30.2M | 32.02M | 20.93M | 17.63M | 14.71M | 14.94M | 12.68M | 11.72M | 9.74M | 8M | 7.08M | 7.63M | 8.64M | 10.13M | 9.37M | 9.86M | 8.12M | 6.57M |
| Research and Development Revenue Growth | +3.41% | +5.71% | -0.48% | -17.19% | +9.29% | -3.75% | +3.12% | +7.06% | +9.09% | +1.21% | +3.81% | -14.39% | +3.75% | +15.55% | +17.43% | -29.07% | -8.07% | -74.11% | +1318.45% | -3.68% | -24.91% | +0.66% | +23.69% | +15.70% | -5.66% | +52.95% | +18.72% | +19.84% | -1.49% | +17.83% | +8.10% | +20.42% | +21.68% | +12.99% | -7.12% | -11.75% | -14.68% | +8.13% | -5.05% | +21.54% | +23.50% | n/a |
| Sales and Marketing Revenue | 247.12M | 264.31M | 91.2M | 194.65M | 51.8M | 50.4M | 57.59M | 173.16M | 176.49M | 186.96M | 210.21M | 66M | 72.8M | 232.18M | 284.3M | 196.62M | 194.83M | 186.14M | 166.83M | 136.48M | 118.86M | 167.75M | 119.85M | 86.2M | 88.19M | 90.94M | 76.77M | 64.84M | 54.43M | 53.41M | 40.63M | 37.77M | 36.73M | 38.8M | 30.51M | 26.31M | 30.3M | 25.71M | 21.94M | 23.08M | 20.59M | 16.52M |
| Sales and Marketing Revenue Growth | -6.50% | +189.81% | -53.15% | +275.78% | +2.78% | -12.48% | -66.74% | -1.89% | -5.60% | -11.06% | +218.50% | -9.34% | -68.65% | -18.33% | +44.60% | +0.92% | +4.67% | +11.58% | +22.23% | +14.82% | -29.14% | +39.96% | +39.04% | -2.26% | -3.02% | +18.45% | +18.41% | +19.12% | +1.92% | +31.46% | +7.57% | +2.83% | -5.34% | +27.19% | +15.96% | -13.18% | +17.85% | +17.17% | -4.92% | +12.07% | +24.62% | n/a |